{
  "id": 15080299,
  "title": "CytomX CEO Sean McCarthy sells $461,906 in stock",
  "url": "https://urgent.news/2026/10/17/cytomx-ceo-sean-mccarthy-sells-461-906-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-17T00:01:10.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/cytomx-ceo-sean-mccarthy-sells-461906-in-stock-93CH-4955027"
  },
  "original_language": "en",
  "account": "CEO Sean McCarthy of CytomX Therapeutics, Inc. (NASDAQ:CTMX) divested 101,793 shares of the company's common stock on November 6, 2025, amounting to $461,906. This trade was conducted via a pre-established Rule 10b5-1 trading plan, which was approved on August 27, 2024. The shares were traded at an average price of $4.5377, within a price spectrum of $4.50 to $4.62. Subsequent to the sale, CTMX's stock value has plummeted substantially, presently trading at $2.28—a 52.7% decrease over the past half-year. Before the sale, McCarthy exercised options to purchase the same quantity of shares, 101,793, at an exercise price of $1.59 each, totaling $161,850. This exercise was fully vested and exercisable. This amendment report revises an error from the initial filing on November 10, 2025, which had inadvertently omitted the exercised shares. Following these transactions, McCarthy now directly owns 1,089,684 shares of CytomX Therapeutics common stock, including 488,750 restricted stock units. An additional 93,158 shares are held indirectly by the Sean A. McCarthy 2018 Trust, of which McCarthy is the trustee. Projections from InvestingPro suggest that CTMX may be slightly undervalued at present and are included in the platform's 'most undervalued stocks' watchlist, alongside 12 extra ProTips for comprehensive investment analysis. Concurrently, CytomX Therapeutics disclosed underwhelming financials for Q2 2026, recording an adjusted loss of $0.09 per share, surpassing analysts' forecast of a $0.08 loss. Revenue also fell short, totaling $1.4 million compared to an anticipated $11.33 million. Despite these figures, analysts highlighted the company's significant cash reserves and a fresh milestone payment from Regeneron. Following the earnings release, Guggenheim adjusted its price target for CytomX to $14 while maintaining a Buy rating. Cantor Fitzgerald, on the other hand, retained its Overweight rating with a $12 price target, pointing to a potential turning point for the company. CytomX Therapeutics also revealed advancements in its lead program, Varseta-M, and plans for a colorectal cancer update later in 2026, as the firm grapples with financial hurdles and strategic progressions. This report was produced with the assistance of AI and edited by a journalist. For additional details, refer to our Terms and Conditions.",
  "summary": null,
  "key_points": [
    "CEO Sean McCarthy sold 101,793 shares of CytomX Therapeutics at $4.5377 average price",
    "Sale value $461,906; stock dropped 52.7% to $2.28 in 6 months",
    "McCarthy now owns 1,089,684 shares including 488,750 RSUs"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "German American Bancorp director Andrew Seger buys $100 in shares",
        "url": "https://urgent.news/2026/10/16/german-american-bancorp-director-andrew-seger-buys-100-in-shares",
        "published": "2026-10-16T19:01:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}